XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Testing revenue $ 191.9 $ 156.4 $ 556.6 $ 500.6
Costs and expenses:        
Cost of testing revenue 57.6 50.4 174.6 148.1
Research and development expense 24.0 20.5 67.7 62.0
Selling, general, and administrative expense 136.1 130.5 428.5 368.2
Legal charges pending settlement 34.3 0.0 111.8 0.0
Goodwill and long-lived asset impairment charges 0.0 0.0 0.0 10.7
Total costs and expenses 252.0 201.4 782.6 589.0
Operating loss (60.1) (45.0) (226.0) (88.4)
Other income (expense):        
Interest income 0.6 1.1 1.8 1.6
Interest expense (1.0) (0.8) (2.0) (2.3)
Other (0.7) 0.5 (3.7) 0.6
Total other expense, net (1.1) 0.8 (3.9) (0.1)
Loss before income tax (61.2) (44.2) (229.9) (88.5)
Income tax expense (benefit) 0.1 (9.1) 2.2 (18.8)
Net loss $ (61.3) $ (35.1) $ (232.1) $ (69.7)
Net loss per share:        
Basic (dollars per share) $ (0.75) $ (0.43) $ (2.84) $ (0.87)
Diluted (dollars per share) $ (0.75) $ (0.43) $ (2.84) $ (0.87)
Weighted average shares outstanding:        
Basic (shares) 81.9 80.7 81.6 80.4
Diluted (shares) 81.9 80.7 81.6 80.4
Revenue from contract with customer, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member]
Cost, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member]